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Patients receiving treatment for acute myelogenous leukemia (AML) and recipients of allogeneic stem cell
transplantation (aSCT) are at high risk of contracting Clostridium difﬁcile infection (CDI), the most frequently
observed nosocomial diarrhea and enterocolitis. Data were retrieved from the prospective Cologne Cohort of
Neutropenic Patients. Patients hospitalized for aSCT as well as patients receiving treatment for AML were
included in the analysis. Risk factor analysis for the occurrence of CDI was performed by backward-stepwise
logistic regression (P < .1). During the period from January 2007 to August 2010, 310 hospitalizations of 152
patients with AML and 229 hospitalizations of 223 patients undergoing aSCT were eligible for analysis.
Incidence rates for CDI per 10,000 patient days were 17.9 for AML patients and 27.4 for aSCT recipients.
Among AML and aSCT patients, median time from initiation of chemotherapy to CDI was 10 days (range, 8 to
101 days) and 17 days (range, 6 to 79), respectively. Logistic regression identiﬁed carbapenem exposure to be
associated with development of CDI in AML patients (odds ratio [OR], 2.2) and aSCT recipients (OR, 1.4). In
both groups, previous exposure to carbapenems was signiﬁcantly associated with development of CDI. A
follow-up study, assessing the effect of an antibiotic stewardship intervention to decrease the administration
of carbapenems in hematological high-risk patients, is warranted.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION receiving chemotherapy for acute myelogenous leukemia
Clostridium difﬁcile infection (CDI), the most frequently
observed type of nosocomial diarrhea, is deﬁned as the
presence of gastrointestinal symptoms and microbiological
ﬁndings indicating the presence of toxin-producing C. difﬁcile
or colonoscopic ﬁndings showing typical signs of pseudo-
membranous colitis [1,2]. Clinical manifestation is variable,
ranging from mild or moderate diarrhea to fulminant, life-
threatening pseudomembranous colitis [2].
Earlier studies have identiﬁed a variety of risk factors
associated with development of CDI. Disruption of enteric
ﬂora by antibiotic exposure, especially with cephalosporins
and clindamycin, seems to play a key role in manifestation of
CDI [3]. Concordantly, patient groups with severe immuno-
suppression and high antibiotic exposure, eg, patientsdgments on page 828.
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14.02.022(AML) or undergoing allogeneic stem cell transplantation
(aSCT), were identiﬁed as high-risk populations displaying
incidence rates per hospitalization of 4.8% to 9.3% [4,5] and
12.5% to 30% [6-8], respectively.
In view of these considerably elevated rates, it seems
reasonable to identify and explore potentially preventive
measures. In addition, it has been hypothesized that gastro-
intestinal graft-versus-host disease (GVHD), a severe com-
plication in aSCT recipients, may be triggered by CDI [7,9-11].
Preventing CDI may, therefore, reduce the incidence of
gastrointestinal GVHD, with the potential of reducing severe
morbidity and even mortality.
Previous publications have shown that antibiotic stew-
ardship may effectively decrease the rate of CDI [12,13];
however, identiﬁcation of antimicrobials driving develop-
ment of CDI in these high-risk populations would have to
precede such an intervention. Only a few authors have
assessed risk factors for CDI in patients undergoing treat-
ment for AML [4] and recipients of an aSCT [7,8]. TheseTransplantation.
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myeloablative conditioning regimens with high doses of to-
tal body irradiation (TBI) were still the predominant treat-
ment strategy. Furthermore, only 1 of these studies evaluated
different classes of antibiotics as independent risk factors [7].
However, some standard-of-care agents for patients with
febrile neutropenia, eg, the carbapenems [14], were not
included into this analysis.
Further studies are needed to identify potential targets for
an antibiotic stewardship intervention that might decrease
the incidence of CDI in hematological high-risk patients. To
this end, we performed a prospective cohort study that
assessed the epidemiology of and risk factors for CDI at the
Department I of Internal Medicine, University Hospital of
Cologne, Germany.
DESIGN AND METHODS
Trial Design
For this study, data were retrieved from the prospective Cologne
Cohort of Neutropenic Patients, analyzed, and reported in agreement with
Strengthening the Reporting of Observational Studies in Epidemiology
statement [15]. The Cologne Cohort of Neutropenic Patients is a non-
interventional cohort in which data on risk factors, interventions, and
outcome of immunocompromised patients at risk of opportunistic in-
fections are collected (NCT01821456). Data from all patients undergoing
chemotherapy at the Department I of Internal Medicine at the University
Hospital of Cologne, Cologne, Germany, are incorporated into the
database.
Data capture included demographic data; gender; weight; height; un-
derlying disease; dates of admission and discharge; type of conditioning
treatment; type of transplantation; duration of neutropenia; information on
donor mismatch status; cytomegalovirus status of transplant donor and
recipient; occurrence and severity of acute GVHD; onset and duration of
diarrhea; C. difﬁcile toxin test results; administration of antimicrobials,
proton pump inhibitors (PPI), and immunosuppressants; use of hemato-
poietic growth factors; admission to intensive care unit; follow-up duration;
and survival.
For documentation, a custom platform based on Microsoft SQL Server
2005 and Microsoft Access 2007 (both by Microsoft Corporation, Redmond,
WA) was developed in cooperation with System AG für IT-Lösungen,
Lohmar, Germany.
Additional datawere obtained from the gastroenterology unit, including
macroscopic and histological ﬁndings of all colonoscopies and sigmoidos-
copies carried out in the documented period to identify all patients inwhom
an acute GVHD or pseudomembraneous colitis was diagnosed.
Setting
All patients were diagnosed and treated in accordance with local hos-
pital care standards, which are deﬁned during regular meetings by spe-
cialists in oncology, hematology, transplantation medicine, and infectious
diseases. Patients receiving treatment for acute leukemia received antibiotic
prophylaxis with trimethoprim and sulfomethoxazole. Fluoroquinolone
prophylaxis was provided to transplant recipients with the start of the
conditioning regimen. AML patients were treated in a regular ward in single
or double rooms. All aSCT recipients were treated in single roomswith high-
efﬁciency particulate absorption ﬁltration on an isolation ward.
Study Patients and Patient Groups
All consecutive patients hospitalized at the Department I of Internal
Medicine for an aSCT and patients receiving treatment for AML during the
period from January 2007 to August 2010 were included into the analysis.
Earlier patients were excluded because of major changes in treatment
practice in 2006 (introduction of posaconazole for AML patients and abol-
ishment of sterile care for aSCT recipients). There were no formal exclusion
criteria. Because of substantial differences in potential risk factors, patient
groups (AML patients and aSCT recipients) were analyzed separately.
Deﬁnitions and Endpoints
Diarrhea was deﬁned as 3 or more unformed stools within 24 hours or
> 600 mL unformed stool in patients with a rectal stool collector.
A case of CDI was deﬁned according to the European Society of Clinical
Microbiology and Infectious Diseases [1]. The diagnosis of CDI was
conﬁrmed when a patient presented with diarrhea and a stool test was
positive for toxin-producing C. difﬁcile. We required a positive stool toxin
assay at most 4 days before or after diarrhea for diagnosis of CDI. The toxinassay used by the hospitals laboratory at the time of the study was an EIA for
toxin A and B (RIDASCREEN, R-Biopharm, Darmstadt, Germany). Only un-
formed stool samples are tested for C. difﬁcile toxin in our microbiology
department. Relapse of CDI was deﬁned as new onset of CDI as deﬁned
above after at least 7 days without clinical symptoms of CDI.
Neutropenia was deﬁned as an absolute neutrophil count of less than
500 neutrophils/mL or, if not available, a white blood cell count of less than
1000 leukocytes/mL.
The observational period started with admission and ended upon
discharge from hospital or death, whichever occurred ﬁrst.
Acute GVHD of the gastrointestinal tract was diagnosed by histology
obtained during endoscopy (sigmoidoscopy or colonoscopy). If there was no
pathologic report available, diagnosis was exclusively based on macroscopic
endoscopic evaluation.
Response to CDI treatment was deﬁned as resolution of diarrhea within
10 days of speciﬁc antibiotic therapy (metronidazole i.v./per oral [p.o.] and/
or and vancomycin p.o.). When a combination of both antibiotics was used,
beginning of antibiotic treatment was the ﬁrst day of administration of the
ﬁrst substance used.
Data Analysis and Endpoints
Statistical analyses were carried out using IBM SPSS Statistics software
(version 21, IBM Corporation, Armonk, NY). Analysis of frequencies was
performed in a descriptive fashion. Risk factor analyses for the occurrence of
CDI (AML patients and aSCT recipients) and of acute gastrointestinal GVHD
(aSCT recipients only) were performed by backward-stepwise logistic
regression analysis. Potential risk factors were eliminated on P  .1.
Variables were preselected based on a literature search on potential risk
factors and confounders. For AML patients, the following variables were
included into the analysis: age > 60 years; chemotherapy type; duration of
neutropenia; duration of hospitalization; administration of cephalosporins,
ﬂuorquinolones, acylaminopenicillinþß-lactamase inhibitors, carbapenems,
glycopeptides, and aminoglycosides; overall number of antibiotics; and PPI
administration [3,4,16]. For the detection of potential risk factors for CDI in
aSCT recipients, the following variables were included into the analysis: age
> 60 years; underlying condition; conditioning regimen; chemotherapy
before aSCT; duration of neutropenia; duration of hospitalization; TBI
 12 Gy; acute gastrointestinal GVHD; administration of ﬂuorquinolones,
acylaminopenicillinþß-lactamase inhibitors, carbapenems, and glycopep-
tides; overall number of antibiotics; and PPI administration [3,7,8,11,16]. As
opposed to the analysis for the group of patients with AML, this analysis did
not include cephalosporins, as they are not part of our standard of care in
aSCT patients.
For the detection of potential risk factors for acute gastrointestinal
GVHD in aSCT recipients, the following variables were included into the
analysis: age > 60, cytomegalovirus donor status, mismatches, TBI  12 Gy,
CDI, and glycopeptide administration [7,9-11,17]. For all logistic regression
analyses, only the ﬁrst hospitalization of each patient was used.
Ethical Statement
This study is a strictly observational epidemiological cohort study.
Only data that were collected as part of standard care have been analyzed.
All authors were directly involved in patient care at the University Hospital
of Cologne. Data were collected and stored on site in accordance with
current techniques of privacy assurance. Under these circumstances, ac-
cording to x 15 subparagraph 1 “Berufsordnung für die nordrheinischen
Ärztinnen und Ärzte” (code of medical ethics for physicians in the state of
Northrhine-Westfalia) [18] and x 6 subparagraph 2 “Gesundheitsdaten-
schutzgesetz - GDSG NRW” (health privacy law for the state of Northrhine-
Westfalia) [19], no formal vote by an ethics committee or informed
consent was necessary for this study.
RESULTS
A total of 310 hospitalizations of 153 patients receiving
treatment for AML and 235 hospitalizations of 229 patients
receiving aSCT were identiﬁed. After exclusion of hospitaliza-
tionswith incompleteﬁles, 310hospitalizationsof153patients
with AML and 229 hospitalizations of 223 patients under-
going aSCT were eligible for further analysis (Supplementary
Figure 1).
C. Difﬁcile Infection in AML Patients
Detailed characteristics during ﬁrst documented episodes
of patients with AML and patients receiving aSCT are
shown in Tables 1 and 2, respectively. The majority of
Table 2A
Characteristics of aSCT Recipients with and without CDI
Recipients of an aSCT
Variables First
Hospitalizations
without CDI
(n ¼ 195)
First
Hospitalizations
with CDI (n ¼ 28)
Age, yr
Mean and SD 47.4  14.1 45.0  11.1
Range 17-72 21-63
Female 86 (44.1) 7 (25)
BMI
Mean and SD 24.6  4.2 24.7  4.1
Range 16.5-46.6 17.6-32.7
Underlying condition
Acute leukemia 124 (63.6) 18 (64.3)
Chronic leukemia 19 (9.7) 3 (10.7)
Lymphoma 45 (23.1) 6 (21.4)
Other* 7 (3.6) 1 (3.6)
Conditioning regimen
Myeloablative 40 (20.5) 6 (21.4)
RIC 155 (79.5) 22 (78.6)
TBI 12 Gy 22 (11.3) 5 (17.9)
Donor type
MRD 62 (31.8) 7 (25.0)
MismRD 4 (2.1) 1 (3.6)
MUD 87 (44.6) 9 (32.1)
MismUD 42 (21.5) 11 (39.3)
Mismatches
10/10 149 (76.4) 16 (57.1)
9/10 43 (22.1) 9 (32.1)
8/10 3 (1.5) 3 (10.7)
CMV serostatus donor/recipient
Donor þ/recipient þ 19 (19.7) 5 (17.9)
Donor /recipient 124 (63.6) 13 (46.4)
Donor þ/recipient 45 (23.1) 5 (17.9)
Donor /recipientþ 7 (3.6) 5 (17.9)
Duration of neutropenia, d
Mean and SD 21.4  12.5 27.0  13.7
Range 0-102 8-64
Duration of hospitalization, d
Mean and SD 43.2  17.9 54.3  26.0
Range 14-120 17-114
Intensive care, d
Mean and SD 13.4  15.1 10.4  9.2
Range 1-62 2-24
Immunosuppressants received
Calcineurin inhibitors 182 (93.3) 26 (92.9)
MMF 149 (76.4) 24 (85.7)
ATG 55 (28.2) 7 (25.0)
Steroids 159 (81.5) 21 (75.0)
Acute GI GVHD 7 (3.6) 4 (14.3)
Antibiotics received
Carbapenem 87 (44.6) 21 (75.0)
Fluoroquinolone 185 (94.9) 27 (96.4)
Acylaminopenicillinþ
ß-lactamase inhibitor
134 (68.7) 21 (75.0)
Glycopeptide 25 (12.8) 8 (28.6)
PPI received 129 (66.2) 20 (71.4)
ATG indicates antithymocyte globulin; BMI, body mass index; CMV,
cytomegalovirus; GI GVHD, gastrointestinal graft-versus-host-disease;
MismMRD, mismatched related donor; MRD, matched related donor;
MismUD, mismatched unrelated donor; MUD, matched unrelated donor;
MMF, mycofenolate mofetil; PPI, proton pump inhibitor; RIC, reduced-
intensity conditioning; TBI, total body irradiation.
Data presented are n (%) unless otherwise indicated.
* Other includes aplastic anemia (n ¼ 5), osteomyeloﬁbrosis (n ¼ 3), and
idiopathic thrombocytopenia (n ¼ 2).
Table 1
Characteristics of Patients Treated for AML
Variables First
Hospitalizations
without CDI
(n ¼ 142)
First
Hospitalizations
with CDI (n ¼ 11)
Age, yr
Mean and SD 55.7  15.0 52.7  11.4
Range 17-80 32-73
Female, n (%) 79 (51.6) 4 (36.4)
BMI
Mean and SD 26.1  4.6 25.5  5.2
Range 16.0-40.9 17.5-32.9
Chemotherapy, n (%)
Curative 116 (81.7) 10 (90.9)
Palliative 11 (7.7) 1 (9.1)
None 15 (10.6) 0 (0)
Duration of neutropenia, d
Mean and SD 27.7  15.8 32.1  7.8
Range 0-89 20-47
Duration of hospitalization, d
Mean and SD 40.5  22.7 49.9  31.4
Range 1-132 22-139
Intensive care, d
Mean and SD 2.4  6.6 3.27  6.6
Range 0-53 0-23
Antibiotics received, n (%)
Aminoglycoside 64 (45.1) 11 (61.1)
Carbapenem 67 (47.2) 10 (90.9)
Cephalosporin 61 (43.0) 8 (72.7)
Fluoroquinolone 44 (31.0) 4 (36.4)
Acylaminopenicillinþ
ß-lactamase inhibitor
90 (63.4) 5 (45.5)
Glycopeptide 54 (38.0) 6 (54.5)
PPI received, n (%) 88 (62.0) 7 (63.6)
BMI indicates body mass index; PPI, proton pump inhibitor; AML, acute
myelogenous leukemia.
M.J.G.T. Vehreschild et al. / Biol Blood Marrow Transplant 20 (2014) 823e828 825patients (n ¼ 126; 71.9%) treated for AML received intensive
remission-induction chemotherapy during their ﬁrst docu-
mented hospitalizations. The mean duration of neutropenia
was 27.7 days (SD, 15.8 days) and the mean duration of stay
was 41.2 days (SD, 23.5 days). The combination of an
acylaminopenicillinþß-lactamase inhibitor (ie, piperacillin
and tazobactam) was the most frequently used class of an-
tibiotics (n¼ 95; 62.1%), followed by cephalosporins (n¼ 69;
54.9%), and carbapenems (n ¼ 77; 50.3%).
The occurrence rate of diarrheawas 105 of 310 (33.9%) per
hospitalization and 84 of 153 (54.9%) per patient. C. difﬁcile
infection occurred in 19 of 310 (6.1%) hospitalizations and in
18 of 153 (11.8%) patients; the incidence rate per 10,000 days
was 17.9. The detailed distribution of CDI cases over time is
depicted in Figure 1. Except for a moderate increase in the
number of cases in the fourth quarter of 2009, the incidence
rate in the observed populations was stable. No patient
developing CDI previously shared the room of another AML
patient with CDI. There were 12 AML patients with positive
C. difﬁcile toxin test not fulﬁlling clinical criteria of CDI. No
patient was infected by a NAP1 strain.
Among these patients, 17 of 19 cases of CDI (89.5%)
occurred within 4 weeks of admission. Median time from
initiation of chemotherapy to CDI was 10 days (range, 8 to
101 days). Logistic regression identiﬁed administration of
carbapenems as the most important risk factor for the
development of CDI in AMLpatients. The associated odds ratio
(OR) was 2.2. Administration of an acylaminopenicillinþß-
lactamase inhibitor was identiﬁed as a protective factor with
an ORof .8. Details of logistic regression analyses are shown in
Table 3.C. Difﬁcile Infection in Allogeneic Stem Cell
Transplantation Recipients
In the group of patients undergoing aSCT, acute leukemia
was the most frequently documented reason for performing
aSCT (n¼ 142, 63.7%). Themajority of aSCT were preceded by
reduced-intensity conditioning (n¼ 177, 79.4). Less than half
Figure 1. Distribution of CDI cases over time.
Table 2B
Characteristics of aSCT Recipients with and without Acute Gastrointestinal
GVHD
Variables First
Hospitalizations
without Acute
Gastrointestinal
GVHD (n ¼ 212)
First
Hospitalizations
with Acute
Gastrointestinal
GVHD (n ¼ 11)
Age, yr
Mean and SD 47.1  13.9 46.1  11.5
Range 17-72 22-67
Female 92 (43.4) 1 (9.1)
BMI
Mean and SD 24.5  4.2 25.7  3.7
Range 16.5-46.6 20.0-30.0
Underlying condition
Acute leukemia 133 (62.7) 9 (81.8)
Chronic leukemia 22 (10.4) 0 (0.0)
Lymphoma 49 (23.1) 2 (18.2)
Other* 8 (3.8) 0 (0.0)
Conditioning regimen
Myeloablative 40 (18.9) 6 (54.5)
RIC 172 (81.1) 5 (45.5)
TBI  12 Gy 22 (10.4) 5 (45.5)
Donor type
MRD 69 (32.5) 0 (0.0)
MismRD 5 (2.4) 0 (0.0)
MUD 90 (42.5) 6 (54.5)
MismUD 48 (22.6) 5 (45.5)
Mismatches
0/10 159 (75.0) 6 (54.5)
1/10 50 (23.6) 5 (45.5)
2/10 3 (1.4) 0 (0.0)
CMV serostatus donor/recipient
Donor þ/recipientþ 55 (25.9) 2 (18.2)
Donor /recipient 80 (37.7) 7 (63.6)
Donor þ/recipiente 38 (17.9) 1 (9.1)
Donor /recipientþ 39 (18.4) 1 (9.1)
Duration of neutropenia, d
Mean and SD 22.0  12.8 24.7  12.2
Range 0-102 13-55
Duration of hospitalization, d
Mean and SD 43.3  17.9 68.7  29.9
Range 14-119 35-120
Intensive care, d
Mean and SD 12.9  14.2 12.4  16.6
Range 1-62 2-41
Immunosuppressants received
Calcineurin inhibitors 199 (93.9) 9 (81.8)
MMF 163 (76.9) 10 (90.9)
ATG 59 (27.8) 3 (27.3)
Glucocorticosteroids 170 (80.2) 10 (90.9)
CDI 24 (11.3) 4 (36.4)
Antibiotics received
Carbapenem 99 (46.7) 9 (81.8)
Fluoroquinolone 202 (95.3) 10 (90.9)
Acylaminopenicillinþ
ß-lactamase inhibitor
147 (69.3) 8 (72.7)
Glycopeptide 28 (13.2) 5 (45.5)
PPI received 139 (65.6) 10 (90.9)
aSCT indicates allogeneic stem cell transplantation; ATG, antithymocyte
globulin; BMI, body mass index; CMV, cytomegalovirus; GI GVHD, gastro-
intestinal graft-versus-host-disease; MismMRD, mismatched related donor;
MRD, matched related donor; MismUD,mismatched unrelated donor; MUD,
matched unrelated donor; MMF, mycofenolate mofetil; PPI, proton pump
inhibitor; RIC, reduced-intensity conditioning; TBI, total body irradiation.
Data presented are n (%) unless otherwise indicated.
* Other includes aplastic anemia (n ¼ 5), osteomyeloﬁbrosis (n ¼ 3), and
idiopathic thrombocytopenia (n ¼ 2).
Table 3
Results of Backward-Stepwise Binary Logistic Regression Analysis Assessing
Risk Factors for CDI in Patients with AML and aSCT
Univariate Multivariate
(Only Remaining
Variables)
Variable P Value P Value Odds
Ratio
Dependent variable: CDI in AML patients
Age > 60 .159
Chemotherapy type .440
Duration of neutropenia .336
Duration of hospitalization .197
Cephalosporin .056
Fluoroquinolone .711
Acylaminopenicillinþß-lactamase
inhibitor
.238 .015 .754
Carbapenem .005 .005 2.174
Glycopeptide .280
Aminoglykosides .234
Overall number of antibiotics .175
PPI .931
Dependent variable: CDI in aSCT patients
Age > 60 .137
Underlying condition .901
Conditioning regimen .911
Chemotherapy before aSCT .996
Duration of neutropenia .029
Duration of hospitalization .005
TBI  12 Gy .319
Acute gastrointestinal GVHD .088
Fluoroquinolones .722
Acylaminopenicillinþß-lactamase
inhibitor
.500
Carbapenem .003 .004 1.389
Glycopeptide .028
Overall number of antibiotics .006
PPI .579
AML indicates acute myelogenous leukemia; aSCT, allogeneic stem cell
transplantation; CDI, Clostridium difﬁcile infection; GVHD, gastrointestinal
graft-versus-host-disease; PPI, proton pump inhibitor; TBI, total body
irradiation.
M.J.G.T. Vehreschild et al. / Biol Blood Marrow Transplant 20 (2014) 823e828826of the patients underwent TBI (n¼ 85, 38.1%). Themajority of
the donors were matched unrelated donors (n ¼ 96, 43.0%)
or matched related donors (n ¼ 69, 30.9%). The mean dura-
tion of neutropenia and length of stay were 22.1 days (SD,
12.8 days) and 44.6 days (SD, 19.4 days), respectively. For
immunosuppression, calcineurin inhibitors were selected in208 hospitalizations (93.9%). Fluoroquinolone prophylaxis
was administered in 212 hospitalizations (95.1%). The com-
bination of an acylaminopenicillinþß-lactamase inhibitor
was the class of antibiotics most frequently used for treat-
ment (n ¼ 155, 69.5%), followed by the carbapenems
(n ¼ 108, 48.4%).
The occurrence rate of diarrhea was 177 of 229 (77.3%) for
hospitalizations and 172 of 223 (77.1%) for patients. Incidence
rate of CDI was 27.4 per 10,000 patient days in aSCT re-
cipients, yielding a crude incidence of 28 of 223 (12.6%) for
hospitalizations and 30 of 229 (13.1%) for patients.
M.J.G.T. Vehreschild et al. / Biol Blood Marrow Transplant 20 (2014) 823e828 827Among aSCT recipients, 23 of 28 cases (82.1%) occurred
within the ﬁrst month after transplantation. Median time
from initiation of chemotherapy to CDI was 17 days (range, 6
to 79). Except for a moderate increase in the number of cases
in the fourth quarter of 2009, the incidence rate in the
observed populations was stable (Figure 1). None of these
patients shared the room of another aSCT patient with CDI.
There were 6 aSCT patients with positive C. difﬁcile toxin test
results not fulﬁlling clinical criteria of CDI. No patient was
infected by a NAP1 strain.
In aSCT recipients, carbapenem exposure was identiﬁed
as a risk factor by logistic regression, with an associated OR of
1.4. Details are given in Table 3.
Concerning risk factors for the development of acute
gastrointestinal GVHD, logistic regression analysis identiﬁed
TBI >12 Gy (OR, 8.2), CDI (OR, 3.3), and glycopeptide expo-
sure (OR, 1.2) as relevant. Details are given in Table 4.Treatment Results for CDI
Most patients received CDI therapy with oral metroni-
dazole (AML patients, 9 of 18; 50.0% and aSCT patients, 14 of
28; 50.0%). In only 1 patient of each group, oral vancomycin
was administered, exclusively. In 5 hospitalizations of AML
patients and 9 hospitalizations of aSCT patients, a combina-
tion of oral vancomycin and metronidazole (i.v. and/or p.o.)
was used. In 3 AML episodes and 4 aSCT hospitalizations, no
speciﬁc therapy was administered and diarrhea resolved
spontaneously.
For metronidazole monotherapy, the response rate at day
10 was 66.7% in AML episodes and 64.3% in aSCT hospitali-
zations. Mean time to resolution of diarrhea was 8.9 and
8.1 days, respectively. For patients receiving a combination of
metronidazole and vancomycin, the response rate was 20.0%
in AML hospitalizations and 37.5% in aSCT hospitalizations.
Mean time to success was 13.6 and 20.3 days, respectively.
Only 1 patient in the AML group had a documented relapse.DISCUSSION
The present study assessed the epidemiology and treat-
ment of CDI, as well as associated risk factors in patients
being treated for AML and those undergoing aSCT. CDI inci-
dence rates per 10,000 patient days were 17.9 for AML pa-
tients and 27.4 for aSCT recipients. The incidence rate of CDI
per hospitalization was 6.1% and 12.6%, respectively. These
data are in concordancewith results from previous studies in
the respective patient populations [4,7,8,10,11,20-22]. For theTable 4
Results of Backward-Stepwise Binary Logistic Regression Analysis Assessing
Risk Factors for Acute Gastrointestinal GVHD in aSCT Patients
Dependent Variable: Acute Gastrointestinal GVHD in aSCT Patients
Univariate Multivariate (Only
Remaining Variables)
Variable P Value P Value Odds Ratio
Age > 60 .303
Underlying condition .281
CMV status .278
Mismatches .229
TBI  12 Gy .001 .003 8.155
CDI .015 .098 3.286
Glycopeptide .003 .014 1.211
aSCT indicates allogeneic stem cell transplantation; CDI, Clostridium difﬁcile
infection; GVHD, gastrointestinal graft-versus-host-disease; PPI, proton
pump inhibitor; TBI, total body irradiation.ﬁrst time, we were able to pinpoint carbapenem use as a
main driver of CDI in hematological patients.
In our population of AML patients, administration of car-
bapenems was the only independent risk factor. Schalk et al.
identiﬁed duration of neutropenia and antibiotic treatment
with ceftazidime as independent risk factors for the devel-
opment of CDI in AML patients receiving cytarabine-based
induction chemotherapy [4]. These risk factors could not be
conﬁrmed by our analysis; however, it should be pointed out
that ceftazidime is not used for the treatment of febrile
neutropenia in our department and could, therefore, not be
assessed. Concerning recipients of aSCT, 3 previous studies
have analyzed 185, 205, and 407 aSCT hospitalizations and
identiﬁed cord blood SCT, TBI 12 Gy, acute GVHD, receipt of
chemotherapy before conditioning for aSCT, age > 60 years,
broad-spectrum antimicrobial use, and colonization with
vancomycin-resistant enterococci as risk factors for CDI
[7,8,11]. Wherever possible, the variables used in our logistic
regression analysis were deﬁned to allow comparison with
previous analyses. Because none of our patients received cord
blood transplantation, we were not able to assess this vari-
able. Total body irradiation  12 Gy, age > 60 years, and
administration of chemotherapy before conditioning for aSCT
were not conﬁrmed by our analysis. However, these differ-
ences might reﬂect underlying changes in transplantation
practices, as our patient population included more recently
performed transplantations. As an example, myeloablative
conditioning regimens and TBI  12 Gy are currently being
superseded by reduced-intensity conditioning with reduced
TBI or no TBI at all in response to the increasing age and co-
morbidity of aSCT recipients.
Of note, an important previously identiﬁed risk factor that
is not involved in the choice of conditioning treatment, ie,
exposure to broad-spectrum antibiotics, was conﬁrmed by
our logistic regression analysis. Exposure to carbapenems
was associated with an OR of 1.4. Development of CDI and
colonization with vancomycin-resistant enterococci are both
considered the result of dysbiosis after antibiotic exposure
[23,24]. Our identiﬁcation of the carbapenems as the most
important risk factor for CDI in both AML and aSCT patients is
supported by results from a large meta-analysis of 33 trials,
in which empirical antibiotic monotherapy for febrile neu-
tropenia with a carbapenem was associated with a relative
risk of developing CDI of 1.94 (conﬁdence interval, 1.24 to
3.04; n ¼ 2025) [16]. Given the identiﬁcation of carbapenem
exposure as a signiﬁcant risk factor for CDI in both groups
(AML patients and aSCT recipients), they might indeed
represent a reasonable target for an antibiotic stewardship
intervention.
There was no major change in our CDI case rate per
quarter. Rates peaked once during the fourth quarter of
2009; however, this increase did not persist (Figure 1). These
stable rates over time are somewhat surprising, as the inci-
dence rate of CDI has repetitively been reported as being on a
substantial rise since the emergence of the NAP1 strain in
North America and Europe [25,26]. It seems that, to date, the
presence of this hyper-virulent strain in Europe is limited to
regional outbreaks. Strains other than NAP1 account for the
majority of CDI cases [27].
Finally, our assessment of the relationship between the
occurrence of CDI and consecutive acute gastrointestinal
GVHD showed a signiﬁcant association (OR, 3.3), conﬁrming
ﬁndings from previous analyses [7,9-11]. In this context, the
increasing number of publications linking major shifts in the
composition of the intestinal microbiota to the occurrence of
M.J.G.T. Vehreschild et al. / Biol Blood Marrow Transplant 20 (2014) 823e828828gastrointestinal GVHD should be pointed out. Jenq et al.
could show that administration of ampicillin led to the
elimination of Lactobacillales from the intestinal microbiota
of mice undergoing bone marrow transplantation [17]. As
opposed to mice that had not received ampicillin treatment,
these mice also experienced aggravated gastrointestinal
GVHD. The authors report that analogous patterns could be
identiﬁed in fecal samples of human aSCT recipients. If acute
gastrointestinal GVHD can indeed be triggered by a loss of
diversity in the composition of the intestinal microbiota, the
strong link to the previous occurrence of CDI is easily
explained by the fact that CDI itself is a marker of severe
dysbiosis.
In conclusion, our study showed considerable CDI inci-
dence rates of 17.9 cases per 10,000 AML patient days and of
27.4 per for 10,000 patient days of aSCT recipients. In both
groups, previous exposure to carbapenems was identiﬁed
as a signiﬁcant risk factor for the development of CDI.
Furthermore, CDI itself was shown to be a risk factor for the
development of acute gastrointestinal GVHD. These ﬁndings
underscore the potential dangers of dysbiosis of the gut
microbiota. A follow-up study, assessing the effect of an
antibiotic stewardship intervention to decrease the admin-
istration of carbapenems in hematological high-risk patients
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